Ovagen: Reference Overview and Reconstitution Notes

Ovagen is a man-made, very short protein fragment called a peptide. It belongs to a group called Khavinson bioregulators, which are sorted by the tissue each one is studied for. Ovagen is grouped under liver and gut tissue. It is a research-only compound and is not approved by the FDA.

Ovagen

What it is

Ovagen is a man-made, very short protein fragment. Scientists call it a tripeptide, which just means it is built from exactly three amino acids. Amino acids are the small building blocks that link together to form all proteins. The three amino acids here are glutamic acid, aspartic acid, and leucine, often written as Glu-Asp-Leu (EDL).

Ovagen belongs to the Khavinson class of peptide bioregulators. This is a family of very short, man-made peptides developed and studied at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia. Each member of the family is grouped by the specific body tissue it is thought to affect.

Key point: Ovagen is a man-made tripeptide being studied in research settings for its effects on liver and gut tissue. It is not FDA-approved and has not been proven to treat any condition.

Research context and categorization

Proposed Mechanism

Ovagen is classed as a liver and gut tissue bioregulator within the Khavinson family. A bioregulator, in plain terms, is a compound thought to help a specific tissue stay stable and working normally.

The leading research idea is that these short peptide chains may interact with DNA and chromatin inside a cell. Chromatin is the material that packages and organizes DNA, a bit like a spool that thread is wound around. By interacting with that spool, the peptide may nudge which genes are switched on or off in certain tissues. This is a research hypothesis, meaning it is an idea still being tested, not a settled fact.

Areas of Investigation

Researchers study Ovagen mainly in relation to liver (hepatic) tissue and the lining of the gut. One focus is homeostasis, which means keeping a tissue stable and balanced, much like a thermostat keeps a room at a steady temperature. Studies have looked at age-related changes in liver structure, liver tissue upkeep, and gut barrier markers such as tight-junction proteins. Tight-junction proteins work like mortar between bricks, holding the cells of the gut lining tightly together.

All of these uses are investigational, meaning they are still under study. Ovagen is not FDA-approved. The effects described in early research, which comes mostly from non-Western literature, are not confirmed or established benefits. Any claim that Ovagen treats, reverses, or cures a liver or digestive condition should be treated as unproven.

Status

• Regulatory status: Research-only. Ovagen is not approved by the FDA for any use. It is not a drug, food, cosmetic, or dietary supplement. It has been studied mostly in lab and animal work (called preclinical research), with no published human clinical trials.
• Sport status: Ovagen is not listed by name on the WADA Prohibited List (the banned substance list from the World Anti-Doping Agency). However, WADA bans broad categories of substances, including peptide hormones, growth factors, and related compounds. The list also includes catch-all language that covers compounds with a similar structure or biological effect. Because Ovagen is an unapproved research peptide, where it stands under those broader categories can be unclear. Anyone subject to drug testing should check current WADA guidance directly.

Reconstitution notes (general)

Lyophilized (freeze-dried) peptides come as a dry powder. Think of instant coffee, which is a liquid that has had all its water removed to make a shelf-stable powder. To prepare a freeze-dried peptide for lab use, you add bacteriostatic water to the vial. Bacteriostatic water is a purified water that contains a small amount of preservative to slow the growth of bacteria.

The resulting concentration is a simple ratio: the milligrams (mg) of peptide in the vial divided by the milliliters (mL) of bacteriostatic water you add. For example, a 20 mg vial with 2 mL of bacteriostatic water gives a concentration of 10 mg/mL. You can work out any combination with the calculator at peptide calculator.

Dilution and handling notes (compound-specific)

Ovagen typically comes as a freeze-dried powder in a 20 mg vial. A common range is 1 mL to 3 mL of bacteriostatic water per 20 mg vial, giving a concentration of about 20 mg/mL down to around 6.7 mg/mL. Many researchers add 2 mL to a 20 mg vial because that gives a clean, round 10 mg/mL that is easy to measure accurately.

Physical Characteristics

Because Ovagen is such a tiny peptide, it dissolves in water very easily. When you add bacteriostatic water, it should go into solution quickly and cleanly, giving a clear, colorless liquid. It does not tend to turn cloudy, form a gel, or go stringy the way some larger or water-avoiding peptides can when mixed at higher concentrations.

Reconstitution Technique

To keep the solution clean, add the water slowly down the inside wall of the vial rather than squirting it directly onto the powder. Then swirl gently instead of shaking to limit foaming. If a faint haze remains right after adding water, let the vial sit at room temperature for a short time. The last traces of powder usually dissolve on their own.

If the powder does not fully clear, or if the solution turns cloudy later, that is a sign to discard the vial rather than try to force it back into solution. More dilute mixes are easier to measure accurately. More concentrated mixes reduce the total liquid volume in the vial.

Handling and storage

Once mixed, store the vial in the refrigerator at 2 to 8 degrees C and keep it away from direct light. Wipe the rubber stopper with an alcohol swab before and after drawing from the vial, and write the mix date on the label.

A reconstituted vial is generally usable for about four weeks when kept refrigerated. Discard the vial if the contents turn cloudy or change color, or if you see particles or floating bits. Unmixed, freeze-dried vials are best kept cold and protected from light until use. Avoid repeatedly freezing and thawing the mixed solution.

Related reading

• P21
• Pancragen
• PE-22-28
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What amino acids make up Ovagen?

Ovagen is built from three amino acids, glutamic acid, aspartic acid, and leucine, written as Glu-Asp-Leu (EDL). This tripeptide sequence places it in the Khavinson bioregulator family, grouped under liver and gut tissue research.

Is Ovagen FDA-approved for human use?

No. Ovagen is a research-only compound with no FDA approval for any indication. It has no published human clinical trials and is not classified as a drug, dietary supplement, food, or cosmetic.

Is Ovagen on the WADA prohibited list?

Ovagen is not listed by name on the WADA Prohibited List. However, WADA's broad catch-all language covering unapproved peptides and compounds with similar biological effects may apply; classification should be verified with the relevant authority.

What the research community gets wrong about Ovagen

• "Ovagen" is a supplier label, not the chemistry. The actual molecule is the tripeptide Glu-Asp-Leu (EDL), listed in PubChem as glutamyl-aspartyl-leucine (CID 444128). Searching databases by the brand name turns up very little, so search by the sequence or the CID to find the real records.
• The peer-reviewed work is not mostly about liver or gut. Much of the published EDL research looks at kidney tissue in rats, not the liver and gut category often used on product pages. Do not assume a storefront grouping matches where the compound has actually been studied.
• The gene-expression idea is a hypothesis, not a settled fact. The proposal that short peptides bind DNA and shift which genes are active is still being tested, and the authors themselves note the exact mechanism is unclear. Treat it as an open question at the bench, not a proven action.
• Almost all of it is preclinical. The record is cell culture and animal work, with no published human clinical trials. Bench notes should say "studied in" rather than "shown to work."
• "Dissolves easily" does not mean "handle carelessly." Even a small, water-friendly peptide can still degrade with heat, light, and repeated freeze and thaw. Label the mix date, keep the vial cold, and protect it from light.

From our bench: If you reconstitute an EDL (Ovagen) vial, we would like your real numbers. Time how long the powder takes to go fully clear after you add bacteriostatic water down the vial wall and swirl gently, and note the water volume and vial size you used. Then check the same vial once a week in the refrigerator and record the day, if any, on which you first see haze or particles. Send the actual figures you observe, not estimates, and we will add them here.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. PubChem: Glutamyl-aspartyl-leucine (Glu-Asp-Leu, EDL), CID 444128
5. Zamorskii et al., Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis, Bull Exp Biol Med, 2017 (PMID 28744634)
6. Khavinson, Lin'kova, Tarnovskaya, Short Peptides Regulate Gene Expression, Bull Exp Biol Med, 2016 (PMID 27909961)